A Phase 3, Randomized, placebo-controlled, double-blind, Multicenter trial of Selinexor in maintenance therapy after systemic therapy for patients with P53wild-type, advanced or recurrent endometrial carcinoma

Project: Research

Project Details

StatusActive
Effective start/end date21/01/24 → 21/01/26

Keywords

  • clinical trial
  • endometrial carcinoma
  • Selinexor